Overview
XNCR market data
Price History
XNCR price chart · 1M
- O
- 28.18
- H
- 28.90
- L
- 28.02
- C
- 28.62
- Vol
- 54,052.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $28.18
- Previous Close
- $28.45
- Day High
- $28.90
- Day Low
- $28.02
- 52 Week High
- $30.43
- 52 Week Low
- $10.38
- 7 Day Return
- +5.94%
- 30 Day Return
- +43.22%
- 90 Day Return
- +141.07%
- 1 Year Return
- +146.26%
- Daily Notional Volume
- $1.5M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.24 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.89 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -155.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $7.71 – $30.61 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.7B · P/B 1.72 · P/S 16.24.
Company News
RBC Capital Maintains Outperform on Xencor, Raises Price Target to $20Benzinga · Aug 6, 2026, 6:00 PM
Wedbush Maintains Outperform on Xencor, Raises Price Target to $30Benzinga · Aug 6, 2026, 3:43 PM
Cantor Fitzgerald Maintains Overweight on Xencor, Raises Price Target to $44Benzinga · Aug 6, 2026, 12:18 PM
Xencor Q2 EPS $(0.29) Beats $(0.79) Estimate, Sales $51.200M Beat $18.922M EstimateBenzinga · Aug 5, 2026, 8:41 PM
Wedbush Reiterates Outperform on Xencor, Maintains $26 Price TargetBenzinga · Jul 30, 2026, 1:38 PM
Xencor Announces $105M Settlement From Alexion Over US Ultomiris Royalties In Two $52.5M Payments; Ends US Royalties, Extends Operating Runway Through 2028Benzinga · Jul 29, 2026, 8:03 PM
AMC Entertainment, IREN, Hut 8 And Other Big Stocks Moving Higher On MondayBenzinga · Jul 20, 2026, 2:08 PM
Xencor shares are trading higher. The company announced that results from a Phase 1 study of XmAb819 in advanced clear cell renal cell carcinoma were accepted for a proffered paper oral presentation at the ESMO Congress 2026.Benzinga · Jul 17, 2026, 5:48 PM
Xencor Announces Phase 1 Study Results For XmAb819 Antibody Accepted For Proffered Paper Oral Presentation At European Society of Medical Oncology October 23-27Benzinga · Jul 17, 2026, 1:13 PM
Truist Securities Maintains Buy on Xencor, Lowers Price Target to $27Benzinga · Jul 7, 2026, 12:35 PM